Towards cascading genetic risk in Alzheimer’s disease

Andre Altmann,Leon M Aksman,Neil P Oxtoby,Alexandra Young,ADNI,Daniel C Alexander,Frederik Barkhof,Maryam Shoai,John Hardy,Jonathan M Schott

DOI: https://doi.org/10.1101/2023.12.16.23300062

2024-04-21

Abstract:Alzheimer’s disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: Amyloid (A), Tau (T) and neurodegeneration (N). This progression of biomarkers has been condensed into the ATN framework, where each of the biomarkers can be either positive (+) or negative (-). Over the past decades genome wide association studies have implicated about 90 different loci involved with the development of late onset Alzheimer’s disease. Here we investigate whether genetic risk for Alzheimer’s disease contributes equally to the progression in different disease stages or whether it exhibits a stage-dependent effect. Amyloid (A) and tau (T) status was defined using a combination of available PET and CSF biomarkers in the Alzheimer’s Disease Neuroimaging Initiative cohort. In 312 participants with biomarker-confirmed A-T- status, we employed Cox proportional hazards models to estimate the contribution of and polygenic risk scores (beyond ) to convert to A+T- status (65 conversions). Furthermore, we repeated the analysis in 290 participants with A+T- status and investigated the genetic contribution to conversion to A+T+ (45 conversions). Both survival analyses were adjusted for age, sex, and years of education. For progression from A-T- to A+T-, APOE-e4 burden showed significant effect (HR=2.88; 95% CI: 1.70-4.89; P<0.001), while polygenic risk did not (HR=1.09; 95% CI: 0.84-1.42; P=0.53). Conversely, for the transition from A+T- to A+T+, the APOE-e4 burden contribution was reduced (HR=1.62 95% CI: 1.05-2.51; P=0.031), while the polygenic risk showed an increased contribution (HR=1.73; 95% CI:1.27-2.36; P<0.001). The marginal effect was driven by e4 homozygotes (HR=2.58; 95% CI: 1.05-6.35; P=0.039) as opposed to e4 heterozygotes (HR=1.74; 95% CI: 0.87-3.49; P=0.12). The genetic risk for late-onset Alzheimer’s disease unfolds in a disease stage-dependent fashion. A better understanding of the interplay between disease stage and genetic risk can lead to a more mechanistic understanding of transition between ATN stages, a better understanding of the molecular processes leading to Alzheimer’s disease as well as opening therapeutic windows for targeted interventions.

Neurology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether genetic risks play a role in a disease - stage - dependent manner in Alzheimer's disease (AD). Specifically, researchers want to understand whether there are differences in the influence of genetic risk factors (such as the APOE gene and polygenic risk scores) on disease progression at different development stages of Alzheimer's disease.

### Research Background and Problems

Alzheimer's disease is a gradually progressive neurodegenerative disease, and its pathological features include the accumulation of amyloid (A) plaques and phosphorylated tau (T) protein tangles, as well as neurodegeneration (N). Based on the presence or absence of these pathological markers, the development of Alzheimer's disease can be divided into different stages, forming the so - called ATN framework. Under this framework, each marker can be positive (+) or negative (-).

Previous studies have identified approximately 90 gene loci associated with late - onset Alzheimer's disease through genome - wide association studies (GWAS). However, it is still unclear whether these genetic risk factors have the same influence at different disease stages or whether their effects change with disease progression. Therefore, this paper aims to explore the contribution of genetic risk factors at different disease stages, especially the roles of the APOE gene and polygenic risk scores during the transitions from A - T - to A + T - and from A + T - to A + T +.

### Research Methods

The study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and analyzed the effects of the APOE gene and polygenic risk scores on disease progression through the Cox proportional - hazards model. The study subjects were divided into two cohorts:
1. **A - T - Cohort**: 312 participants, among whom 65 transformed from the A - T - state to the A + T - state.
2. **A + T - Cohort**: 290 participants, among whom 45 transformed from the A + T - state to the A + T + state.

### Main Findings

- **Transformation from A - T - to A + T -**:
- The number of APOE - e4 alleles significantly increased the risk of transformation (HR = 2.88; 95% CI: 1.70 - 4.89; P < 0.001).
- The polygenic risk score had no significant effect (HR = 1.09; 95% CI: 0.84 - 1.42; P = 0.53).

- **Transformation from A + T - to A + T +**:
- The number of APOE - e4 alleles still had a significant effect, but the effect was weakened (HR = 1.62; 95% CI: 1.05 - 2.51; P = 0.031), mainly driven by e4 homozygotes (HR = 2.58; 95% CI: 1.05 - 6.35; P = 0.039).
- The polygenic risk score significantly increased the risk of transformation (HR = 1.73; 95% CI: 1.27 - 2.36; P < 0.001).

### Conclusions

This study found that there are significant differences in the roles of genetic risk factors at different development stages of Alzheimer's disease. The APOE - e4 allele has a greater impact in the early stage (from A - T - to A + T -), while its impact is weakened in the late stage (from A + T - to A + T +). Conversely, the polygenic risk score has a more significant impact in the late stage. These findings help to better understand how genetic risk factors affect the progression of Alzheimer's disease and may provide new insights for future treatment strategies.